Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study.
Tada T, Kumada T, Okushin H, Tani J, Takaguchi K, Tsutsui A, Toyoda H, Yasuda S, Dohmen K, Hiraoka A, Michitaka K, Nouso K, Kariyama K, Kim SR, Kim SK, Fujioka S, Mikami S, Watanabe Y, Tamai T, Atsukawa M, Itokawa N, Tanaka H, Tsuji K, Ishikawa T, Imai M, Itobayashi E, Shibata H, Shimada N. Tada T, et al. Among authors: tamai t. Infect Dis Ther. 2021 Mar;10(1):269-280. doi: 10.1007/s40121-020-00364-9. Epub 2020 Nov 3. Infect Dis Ther. 2021. PMID: 33141401 Free PMC article.
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: tamai t. Oncology. 2019;97(5):277-285. doi: 10.1159/000501281. Epub 2019 Jul 15. Oncology. 2019. PMID: 31307035
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Chikara O, Tamai T, Kakizaki S, Tojima H, Nagashima T, Ueno T, Takizawa D, Naganuma A, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), and GLSG (Gunma Liver Study Group). Hiraoka A, et al. Among authors: tamai t. Hepatol Res. 2021 Aug;51(8):880-889. doi: 10.1111/hepr.13644. Epub 2021 May 5. Hepatol Res. 2021. PMID: 33837620
The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Fujisaki K, Hashiguchi M, Inada Y, Uto H, Hiramine Y, Kure T, Hori T, Taniyama O, Kasai A, Tamai T, Moriuchi A, Ido A. Mawatari S, et al. Among authors: tamai t. PLoS One. 2018 Jun 1;13(6):e0198642. doi: 10.1371/journal.pone.0198642. eCollection 2018. PLoS One. 2018. PMID: 29856885 Free PMC article.
Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.
Mawatari S, Kumagai K, Oda K, Tabu K, Ijuin S, Fujisaki K, Tashima S, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hashiguchi M, Tamai T, Hori T, Taniyama O, Toyodome A, Sakae H, Kure T, Sakurai K, Moriuchi A, Kanmura S, Ido A. Mawatari S, et al. Among authors: tamai t. PLoS One. 2022 Jan 12;17(1):e0262267. doi: 10.1371/journal.pone.0262267. eCollection 2022. PLoS One. 2022. PMID: 35020772 Free PMC article.
Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
Tabu K, Mawatari S, Oda K, Kumagai K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hashiguchi M, Tamai T, Hori T, Fujisaki K, Imanaka D, Kure T, Taniyama O, Toyodome A, Ijuin S, Sakae H, Sakurai K, Moriuchi A, Kanmura S, Ido A. Tabu K, et al. Among authors: tamai t. PLoS One. 2020 Aug 13;15(8):e0237475. doi: 10.1371/journal.pone.0237475. eCollection 2020. PLoS One. 2020. PMID: 32790728 Free PMC article.
Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy.
Mawatari S, Oda K, Kumagai K, Tabu K, Ijuin S, Fujisaki K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hori T, Taniyama O, Toyodome A, Sakae H, Hashiguchi M, Kure T, Sakurai K, Tamai T, Moriuchi A, Ido A. Mawatari S, et al. Among authors: tamai t. Hepatol Res. 2020 Apr;50(4):453-465. doi: 10.1111/hepr.13474. Epub 2020 Jan 16. Hepatol Res. 2020. PMID: 31846553
The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area.
Taura N, Fukushima N, Yastuhashi H, Takami Y, Seike M, Watanabe H, Mizuta T, Sasaki Y, Nagata K, Tabara A, Komorizono Y, Taketomi A, Matsumoto S, Tamai T, Muro T, Nakao K, Fukuizumi K, Maeshiro T, Inoue O, Sata M. Taura N, et al. Among authors: tamai t. Med Sci Monit. 2011 Feb;17(2):PH7-11. doi: 10.12659/msm.881375. Med Sci Monit. 2011. PMID: 21278701 Free PMC article.
324 results